Abstract: The present invention provides combinations of active agents, such combinations comprising one or more antifolate compounds. The particularly can include methotrexate and one or more further antifolate compounds. In specific embodiments, the combinations are useful for treating certain conditions, such as rheumatoid arthritis. The invention also provides articles useful to provide the combinations in desirable dosage forms and combinations. The combinations further may be useful in the treatment of further conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis.

Abstract: The present invention provides combinations of active agents, such combinations comprising one or more antifolate compounds. The particularly can include methotrexate and one or more further antifolate compounds. In specific embodiments, the combinations are useful for treating certain conditions, such as rheumatoid arthritis. The invention also provides articles useful to provide the combinations in desirable dosage forms and combinations. The combinations further may be useful in the treatment of further conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis.

Abstract: The present invention provides combinations of active agents, such combinations comprising one or more antifolate compounds. The particularly can include methotrexate and one or more further antifolate compounds. In specific embodiments, the combinations are useful for treating certain conditions, such as rheumatoid arthritis. The invention also provides articles useful to provide the combinations in desirable dosage forms and combinations. The combinations further may be useful in the treatment of further conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis.

Abstract: A method of treating or preventing a condition related to an HPV infection is provided. The method comprises administering to a subject a composition comprising a purified Hsp65-E7 fusion protein (HspE7) admixed with an immune stimulant selected from the group consisting of CpG, a TLR3 agonist such as PolyI:C, PolyICLC, mono-phosphoryl-lipid A (MPL), MPL-trehalose 6,6?-dimycolate (MPL-TDM), and anti-CD40. A composition comprising HspE7 and one or more than one of CpG, a TLR3 agonist such as PolyI:C, PolyICLC, MPL, MPL-TDM, and anti-CD40, and method of reducing a tumor or virus development in a mammal or subject in need thereof by using the composition are also provided.